Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma
出版年份 2021 全文链接
标题
Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-04-14
DOI
10.3389/fphar.2021.643489
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phytochemicals from Carissa carandas with potent cytotoxic and anti-inflammatory activities
- (2021) Zarina Bano et al. NATURAL PRODUCT RESEARCH
- TMEM16A-inhibitor loaded pH-responsive nanoparticles: a novel dual-targeting antitumor therapy for lung adenocarcinoma
- (2020) Shuai Guo et al. BIOCHEMICAL PHARMACOLOGY
- Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy
- (2020) Shuai Guo et al. PHARMACOLOGICAL RESEARCH
- Benzophenanthridine alkaloids suppress lung adenocarcinoma by blocking TMEM16A Ca2+-activated Cl− channels
- (2020) Gaohua Zhang et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- The Role of FAT10 in Alcoholic Hepatitis Pathogenesis
- (2020) Yue Jia et al. Biomedicines
- Evaluation of anticancer effects of a pharmaceutically viable extract of a traditional polyherbal mixture against non-small-cell lung cancer cells
- (2020) Varuni Colamba Pathiranage et al. Journal of Integrative Medicine-JIM
- Molecular mechanism of CaCCinh-A01 inhibiting TMEM16A channel
- (2020) Sai Shi et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: results from a systematic review and network meta-analysis
- (2020) Anupam Kumar Singh et al. Expert Review of Clinical Pharmacology
- Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway
- (2019) Yayun Liu et al. Acta Pharmaceutica Sinica B
- Lung Cancer
- (2019) Faria Nasim et al. MEDICAL CLINICS OF NORTH AMERICA
- Cisplatin: The first metal based anticancer drug
- (2019) Sumit Ghosh BIOORGANIC CHEMISTRY
- Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer
- (2019) K. M. Islam et al. BMC CANCER
- The multifaceted role of TMEM16A in cancer
- (2019) David Crottès et al. CELL CALCIUM
- Entering the spotlight: Chitosan oligosaccharides as novel activators of CaCCs/TMEM16A
- (2019) Shuai Guo et al. PHARMACOLOGICAL RESEARCH
- The Molecular Mechanism of Ginsenoside Analogs Activating TMEM16A
- (2019) Shuai Guo et al. BIOPHYSICAL JOURNAL
- Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease
- (2019) Hirotsugu Kenmotsu et al. CANCER SCIENCE
- Anti-Cancer Activity of a 5-Aminopyrazole Derivative Lead Compound (BC-7) and Potential Synergistic Cytotoxicity with Cisplatin against Human Cervical Cancer Cells
- (2019) Bresler Swanepoel et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2018) Tony S. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Milk thistle (Silybum marianum ): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases
- (2018) Ludovico Abenavoli et al. PHYTOTHERAPY RESEARCH
- Matrine is a novel inhibitor of the TMEM16A chloride channel with antilung adenocarcinoma effects
- (2018) Shuai Guo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator
- (2018) Zohreh Jahanafrooz et al. LIFE SCIENCES
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Cell-specific mechanisms of TMEM16A Ca2+-activated chloride channel in cancer
- (2017) Hui Wang et al. Molecular Cancer
- Ginsenoside Rb1, a novel activator of the TMEM16A chloride channel, augments the contraction of guinea pig ileum
- (2017) Shuai Guo et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
- (2016) Guowei Gu et al. CURRENT OPINION IN PHARMACOLOGY
- Limited resection for early-stage non-small cell lung cancer as function-preserving radical surgery: a review
- (2016) Keiju Aokage et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib
- (2016) Hiroyuki Kobayashi et al. MEDICAL ONCOLOGY
- ANO1 interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer
- (2015) Anke Bill et al. Oncotarget
- Inhibition of Calcium-Activated Chloride Channel ANO1/TMEM16A Suppresses Tumor Growth and Invasion in Human Lung Cancer
- (2015) Linghan Jia et al. PLoS One
- The Ca2+-activated Cl−channel, ANO1 (TMEM16A), is a double-edged sword in cell proliferation and tumorigenesis
- (2014) Zhiqiang Qu et al. Cancer Medicine
- A Rapid and Simple Chromatographic Separation of Diastereomers of Silibinin and Their Oxidation to Produce 2,3-Dehydrosilybin Enantiomers in an Optically Pure Form
- (2013) Giovanni Di Fabio et al. PLANTA MEDICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started